A study to Evaluate AB308 in Combination with AB122 in Participants with Advanced Malignancies (ARC-12)
ARC-12
Phase 1 other active
Quick answer
A study to Evaluate AB308 in Combination with AB122 in Participants with Advanced Malignancies (ARC-12) for Multiple Myeloma, Diffuse large B cell lymphoma (DLBCL), Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Melanoma, Advanced Solid Tumor, Gastrointestinal (GI) cancer, Hematological (heme) cancer, Gynecological (Gyn) cancer, Non-small cell lung cancer (NSCLC), Non-Hodgkin Lymphoma, Gastric Cancer, Cervical Cancer is a Phase 1 program (other) at Arcus Biosciences with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Arcus Biosciences
- Indication
- Multiple Myeloma, Diffuse large B cell lymphoma (DLBCL), Esophageal Cancer, Gastroesophageal Junction Adenocarcinoma, Melanoma, Advanced Solid Tumor, Gastrointestinal (GI) cancer, Hematological (heme) cancer, Gynecological (Gyn) cancer, Non-small cell lung cancer (NSCLC), Non-Hodgkin Lymphoma, Gastric Cancer, Cervical Cancer
- Phase
- Phase 1
- Modality
- other
- Status
- active